ALKERMES PLC overview

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement PR Newswire DUBLIN, Oct. 31, 2023 DUBLIN , Oct. 31 , 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was declared effective by the U.S. Securities and Exchange Commission (SEC). This Form 10 describes Alkermes' planned separation of its oncology business into Mural Oncology, which, upon...

NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Stakeholder Engagement We recognize that our stakeholders - including employees, healthcare providers, patients, caregivers, investors, policy makers, members of the communities where we live and work, and others - are part of a single global community and affect one another. We seek to engage with as many of these stakeholders as we can, so that our approach...

Alkermes plc Reports Third Quarter 2023 Financial Results PR Newswire DUBLIN, Oct. 25, 2023 — Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million — — Company Reiterates Financial Expectations for Full-Year 2023 — — Separation of Oncology Business Expected to be Completed in November 2023 — DUBLIN , Oct. 25, 2023 /PRNewswire/ -- Alkermes...

Alkermes plc Reports Third Quarter 2023 Financial Results PR Newswire DUBLIN, Oct. 25, 2023 — Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million — — Company Reiterates Financial Expectations for Full-Year 2023 — — Separation of Oncology Business Expected to be Completed in November 2023 — DUBLIN , Oct. 25, 2023 /PRNewswire/ -- Alkermes...

NORTHAMPTON, MA / ACCESSWIRE / October 23, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Alkermes' mission is to research, develop and commercialize important new medicines for patients suffering from complex medical conditions, including those who are often unfairly marginalized or stigmatized because of their illness. We also recognize that we are part of a global community facing serious and evolving challenges that threaten our society and...

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire DUBLIN, Oct. 23, 2023 — Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Pharmacokinetic Profile of ALKS 2680 Supports Once-Daily Dosing and Mimics the Natural Sleep/Wake Cycle — — Consistent, Dose-Dependent Effects Enable...

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire DUBLIN, Oct. 23, 2023 — Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Pharmacokinetic Profile of ALKS 2680 Supports Once-Daily Dosing and Mimics the Natural Sleep/Wake Cycle — — Consistent, Dose-Dependent Effects Enable...

Alkermes to Report Third Quarter Financial Results on October 25, 2023 PR Newswire DUBLIN, Oct. 18, 2023 DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Oct. 25, 2023 to discuss the company's third quarter financial results as well as initial clinical data related to ALKS 2680, the company's novel, investigational orexin 2 receptor agonist in development for the treatment of...